A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co. of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp., which the drugmaker bought for $80.3 billion in 2019.